<?xml version="1.0" encoding="UTF-8"?><Articles><Article><id>169</id><JournalTitle>THERAPEUTIC APPROACHES TO TREATING CANCER USING PHARMACOLOGICAL APPROACHES</JournalTitle><Abstract>The development of cancer treatment has changed a lot with the incorporation of high-technological pharmacological
strategies that are aimed at changing the molecular and cellular processes that promote the occurrence and growth of
tumors. The traditional methods, including chemotherapy and radiotherapy, have been crucial, yet with their limitations
(the most noticeable being systemic toxicity and nonspecific cytotoxicity), have led to the creation of more specific
therapeutic approaches. Targeted therapies, such as tyrosine kinase inhibitors, monoclonal antibodies, and antibody-drug
conjugates, are more specific by targeting aberrant receptors, signaling pathways and oncogenic mutations. Checkpoint
inhibitors and PARP inhibitors are immunotherapeutic agents that interfere with anti-tumor and DNA repair
vulnerabilities, respectively. Research in genomic profiling, nanotechnology, and artificial intelligence is only improving
the personal treatment choice, better drug delivery, and therapeutic responses. Combined, these pharmacological advances
have revolutionized the treatment of cancer and enhanced survival rates and decreased morbidity related to treatment</Abstract><Email>ramyasri87428@gmail.com</Email><articletype>Research</articletype><volume>16</volume><issue>2</issue><year>2026</year><keyword>Personalized oncology, Immunotherapy, Synthetic lethality, Targeted therapy, Tyrosine kinase inhibitors</keyword><AUTHORS>Ramya Sri V1*, Harshitha V1, Shaik Suhana Tahrannum1, Diyanka G1, Dr. Purushothaman M</AUTHORS><afflication>Pharm. D Intern, Department of Pharmacy Practice, KLR Pharmacy College, Paloncha, Telangana, India</afflication></Article></Articles>